Biomarkers in malignant pleural mesothelioma: current status and future directions

被引：16
|
作者：
Ahmadzada, Tamkin [1 ]
Reid, Glen [1 ,2 ]
Kao, Steven [2 ,3 ]
机构：
[1] Univ Sydney, Sydney Med Sch, Sydney, NSW, Australia
[2] ADRI, Sydney, NSW, Australia
[3] Chris OBrien Lifehouse, Dept Med Oncol, Sydney, NSW, Australia
来源：
JOURNAL OF THORACIC DISEASE | 2018年 / 10卷
关键词：
DETECT ASBESTOS EXPOSURE; OPEN-LABEL; DIAGNOSIS; PROGNOSIS; TRIAL; OSTEOPONTIN; EXPRESSION; FIBULIN-3; HMGB1;
D O I：
10.21037/jtd.2018.04.31
中图分类号：
R56 [呼吸系及胸部疾病];
学科分类号：
摘要：
引用
收藏
页码：S1003 / S1007
页数：5
相关论文
共 50 条
  • [1] Immunotherapy for malignant pleural mesothelioma: current status and future directions
    Dozier, Jordan
    Zheng, Hua
    Adusumilli, Prasad S.
    TRANSLATIONAL LUNG CANCER RESEARCH, 2017, 6 (03) : 315 - 324
  • [2] The Current Treatment Landscape of Malignant Pleural Mesothelioma and Future Directions
    Bertin, Beatriz
    Zugman, Miguel
    Schvartsman, Gustavo
    CANCERS, 2023, 15 (24)
  • [3] Malignant pleural mesothelioma: current and future perspectives
    Porpodis, Konstantinos
    Zarogoulidis, Paul
    Boutsikou, Efimia
    Papaioannou, Antonis
    Machairiotis, Nikolaos
    Tsakiridis, Kosmas
    Katsikogiannis, Nikolaos
    Zaric, Bojan
    Perin, Branislav
    Huang, Haidong
    Kougioumtzi, Ioanna
    Spyratos, Dionysios
    Zarogoulidis, Konstantinos
    JOURNAL OF THORACIC DISEASE, 2013, 5 : S397 - S406
  • [4] Peritoneal Mesothelioma Current Status and Future Directions
    Chua, Terence C.
    Chong, Chanel H.
    Morris, David L.
    SURGICAL ONCOLOGY CLINICS OF NORTH AMERICA, 2012, 21 (04) : 635 - +
  • [5] Current State-of-the-Art Therapy for Malignant Pleural Mesothelioma and Future Options Centered on Immunotherapy
    Cedres, Susana
    Valdivia, Augusto
    Iranzo, Patricia
    Callejo, Ana
    Pardo, Nuria
    Navarro, Alejandro
    Martinez-Marti, Alex
    Assaf-Pastrana, Juan David
    Felip, Enriqueta
    Garrido, Pilar
    CANCERS, 2023, 15 (24)
  • [6] Epigenetic Alterations and Biomarkers for Immune Checkpoint Inhibitors-Current Standards and Future Perspectives in Malignant Pleural Mesothelioma Treatment
    Yoshikawa, Yoshie
    Kuribayashi, Kozo
    Minami, Toshiyuki
    Ohmuraya, Masaki
    Kijima, Takashi
    FRONTIERS IN ONCOLOGY, 2020, 10
  • [7] Future developments in the management of malignant pleural mesothelioma
    Zucali, Paolo Andrea
    De Vincenzo, Fabio
    Simonelli, Matteo
    Santoro, Armando
    EXPERT REVIEW OF ANTICANCER THERAPY, 2009, 9 (04) : 453 - 467
  • [8] Mesothelin, Calretinin, and Megakaryocyte Potentiating Factor as Biomarkers of Malignant Pleural Mesothelioma
    Jimenez-Ramirez, Carmina
    Casjens, Swaantje
    Arturo Juarez-Perez, Cuauhtemoc
    Raiko, Irina
    Del Razo, Luz M.
    Taeger, Dirk
    Calderon-Aranda, Emma S.
    Rihs, Hans-Peter
    Concepcion Acosta-Saavedra, Leonor
    Weber, Daniel Gilbert
    Cabello-Lopez, Alejandro
    Pesch, Beate
    Dolores Ochoa-Vazquez, Maria
    Burek, Katarzyna
    Torre-Bouscoulet, Luis
    Rogelio Perez-Padilla, Jose
    Marco Garcia-Bazan, Erik
    Bruening, Thomas
    Johnen, Georg
    Aguilar-Madrid, Guadalupe
    LUNG, 2019, 197 (05) : 641 - 649
  • [9] Current insights in malignant pleural mesothelioma
    Bard, M
    Debrosse, D
    Caliandro, R
    Girard, P
    Grunenwald, D
    Ruffié, P
    BULLETIN DU CANCER, 2002, 89 (01) : 67 - 74
  • [10] Current evidence and future perspectives of immune-checkpoint inhibitors in unresectable malignant pleural mesothelioma
    Hotta, Katsuyuki
    Fujimoto, Nobukazu
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2020, 8 (01)
12345